The firm will assess whether adding its CD33-targeted radiotherapy Actimab-A to PD-1 inhibitors will benefit patients more than PD-1 inhibitors alone.

The novel therapy is anticipated to function like PD-1/PD-L1 blockade with significant clinical efficacy results in ...

Cancer impacts millions globally, with lifestyle choices such as smoking, diet, physical activity, alcohol consumption, sun ...

China NMPA approves Akeso's penpulimab for first-line treatment of nasopharyngeal cancer: Hong Kong Tuesday, March 18, 2025, 17:00 Hrs [IST] Akeso Inc., a biopharmaceutical compan ...

Biopharmaceutical company recognized for innovation in the development of immune-modulatory therapeutic cancer vaccines –NEW YORK, March 18, ...

Karnataka: Shilpa Biologicals Pvt Ltd., a fully owned subsidiary of Shilpa Medicare Limited has signed an exclusive ...

AbTree Biologics AG has signed an exclusive co-development and commercialization partnership with Shilpa Biologicals Pvt Ltd. (a fully owned subsidiary of Shilpa Medicare Limited) for its novel ...

Shares of vaccine-maker Moderna MRNA closed at $34.71 on Monday, close to their 52-week low of $29.25. Moderna is facing several headwinds, including the declining COVID-19 vaccine and the soft sales ...

Actinium Pharmaceuticals, Inc. (Actinium or the Company), a pioneer in the development of targeted radiotherapies, today announced a clinical program comprising of trials studying Actimab-A in ...